SCHEMBL1534430

SCHEMBL1534430

COc1ccc2c(=O)c(I)c(-c3ccccc3)oc2c1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 7/20 0.47
ABCC1 P33527 3/20 0.47
CYP1A1 P04798 4/20 0.46
CYP1B1 Q16678 4/20 0.46
CYP1A2 P05177 3/20 0.46
ALDH1A1 P00352 5/20 0.44
MAPT P10636 4/20 0.44
KDM4E B2RXH2 4/20 0.44
CYP3A4 P08684 3/20 0.44
HPGD P15428 3/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
ABCB1 P08183 2/20 0.42
MAOA P21397 3/20 0.41
BCL9 O00512 1/20 0.39
CTNNB1 P35222 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1534410 0.86 MAOA (0.58) ABCG2ABCC1CYP1A1CYP1B1CYP1A2
SCHEMBL1534501 0.83 MAOA (0.57) ABCG2ABCC1CYP1A1CYP1B1CYP1A2
SCHEMBL1534599 0.78 ABCG2 (0.54) ABCG2ABCC1CYP1A1CYP1B1CYP1A2
SCHEMBL1534397 0.76 ACHE (0.54) ABCG2CYP1A1CYP1B1CYP1A2ALDH1A1
SCHEMBL1534579 0.76 ACHE (0.51) ABCG2CYP1A1CYP1B1CYP1A2ALDH1A1
SCHEMBL1534523 0.75 ABCG2 (0.43) ABCG2ABCC1CYP1A1CYP1B1CYP1A2
SCHEMBL1534460 0.75 MEN1 (0.58) ABCG2CYP1A1CYP1B1CYP1A2ALDH1A1
SCHEMBL1534547 0.74 CYP1A1 (0.45) ABCG2ABCC1CYP1A1CYP1B1CYP1A2
SCHEMBL1534531 0.74 AKT1 (0.42) ABCG2ABCC1CYP1A1CYP1B1CYP1A2
SCHEMBL31632545 0.74 CYP3A4 (0.72) ABCG2ABCC1CYP1A1CYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546376-B2 Pharmaceutical compounds ALMAC DISCOVERY LIMITED (GB) 2013-10-01 US disclosed
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2012-09-20 US disclosed
EP-2473495-A1 PHARMACEUTICAL COMPOUNDS Almac Discovery Limited (GB) 2012-07-11 EP disclosed
WO-2011033265-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS PIK3CA, PLK1, MTOR ABCG2 507/4885ABCC1 1213/4885CYP1A1 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.